{"celex_id": "32005D0626", "uri": "http://publications.europa.eu/resource/cellar/b99274a2-c67e-4ff4-9664-9930f37b0235", "type": "Decision", "concepts": ["3468", "3633", "3660", "4455", "5798", "813"], "title": "2005/626/EC: Commission Decision of 23 August 2005 on the allocation of quantities of controlled substances allowed for essential uses in the Community in 2005 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council (notified under document number C(2005) 333)   (Text with EEA relevance)\n", "header": "30.8.2005 EN Official Journal of the European Union L 224/7\nCOMMISSION DECISION\nof 23 August 2005\non the allocation of quantities of controlled substances allowed for essential uses in the Community in 2005 under Regulation (EC) No 2037/2000 of the European Parliament and of the Council\n(notified under document number C(2005) 333)\n(Only the Czech, Danish, Dutch, English, Estonian, Finnish, French, German, Italian, Slovenian, Spanish and Swedish texts are authentic)\n(Text with EEA relevance)\n(2005/626/EC)\nTHE COMMISSION OF THE EUROPEAN COMMUNITIES", "recitals": ",\nHaving regard to the Treaty establishing the European Community,\nHaving regard to Regulation (EC) No 2037/2000 of the European Parliament and of the Council of 29 June 2000 on substances that deplete the ozone layer\u00a0(1), and in particular Article 3(1) thereof,\nWhereas:\n(1) The Community has already phased out the production and consumption of chlorofluorocarbons, other fully halogenated chlorofluorocarbons, halons, carbon tetrachloride,1,1,1-trichloroethane, hydrobromofluorocarbon and bromo-chloromethane.\n(2) Each year the Commission is required to determine essential uses for these controlled substances, the quantities that may be used and the companies that may use them.\n(3) Decision IV/25 of the Parties to the Montreal Protocol on Substances that Deplete the Ozone Layer, hereinafter \u2018the Montreal Protocol\u2019, sets out the criteria used by the Commission for determining any essential uses and authorises the production and consumption necessary to satisfy essential uses of controlled substances in each Party.\n(4) Decision XV/8 of the Parties to the Montreal Protocol authorises the production and consumption necessary to satisfy essential uses of controlled substances listed in Annexes A, B and C (Group II and III substances) of the Montreal Protocol for laboratory and analytical uses as listed in Annex IV to the report of the Seventh Meeting of the Parties, subject to the conditions set out in Annex II to the report of the Sixth Meeting of the Parties, Decision VII/11 and Decision XI/15 of the Parties to the Montreal Protocol.\n(5) Pursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free Metered-Dose Inhalers (MDIs), Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Latvia, Lithuania, Luxembourg, Poland, Norway, Portugal, The Netherlands, Slovak Republic, Slovenia, Spain, Sweden and the United Kingdom have notified the United Nations Environment Programme\u00a0(2) that chlorofluorocarbons (CFCs) are no longer essential for the manufacture of CFC-MDIs that contain active ingredients belonging to the therapeutic categories of \u2018short-acting beta agonist bronchiodilators\u2019, \u2018inhaled steroids\u2019 and \u2018anticholinergic bronchiodilators\u2019. Article 4(4)(i)(b) of Regulation (EC) No 2037/2000 prevents CFCs from being used and placed on the market unless they are considered essential under the conditions described in Article 3(1) of that Regulation. These non-essentiality determinations have reduced the demand for CFCs in the Community. In addition, Article 4(6) of Regulation (EC) No 2037/2000 prevents CFC-MDI products being imported and placed on the market unless the CFCs in these products are considered essential under the conditions described in Article 3(1).\n(6) The Commission has published a Notice\u00a0(3) on the 22 July 2004 to those companies in the Community of 25 Member States that request consideration by the Commission for the use of controlled substances for essential uses in the Community in 2005 and has received declarations on intended essential uses of controlled substances in 2005.\n(7) For the purpose of ensuring that interested companies and operators may continue to benefit in due time from the licensing system, it is appropriate that the present decision shall apply from 1 January 2005.\n(8) The measures provided for in this Decision are in accordance with the opinion of the Management Committee established by Article 18(1) of Regulation (EC) No 2037/2000,", "main_body": ["1.\u00a0\u00a0\u00a0The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) subject to Regulation (EC) No 2037/2000 which may be used for essential medical uses in the Community in 2005 shall be 1\u00a0029\u00a0770,00 ODP\u00a0(4) kilograms.\n2.\u00a0\u00a0\u00a0The quantity of controlled substances of Group I (chlorofluorocarbons 11, 12, 113, 114 and 115) and Group II (other fully halogenated chlorofluorocarbons) subject to Regulation (EC) No 2037/2000 which may be used for essential laboratory uses in the Community in 2005 shall be 63\u00a0081,71 ODP kilograms.\n3.\u00a0\u00a0\u00a0The quantity of controlled substances of Group III (halons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory use in the Community in 2005 shall be 70,705 ODP kilograms.\n4.\u00a0\u00a0\u00a0The quantity of controlled substances of Group IV (carbon tetrachloride) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 145\u00a0240,293 ODP kilograms.\n5.\u00a0\u00a0\u00a0The quantity of controlled substances of Group V (1,1,1-trichloroethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the European Union in 2005 shall be 815,30 ODP kilograms.\n6.\u00a0\u00a0\u00a0The quantity of controlled substances of Group VII (hydrobromofluorocarbons) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 3,04 ODP kilograms.\n7.\u00a0\u00a0\u00a0The quantity of controlled substances of group IX (bromochloromethane) subject to Regulation (EC) No 2037/2000 that may be used for essential laboratory uses in the Community in 2005 shall be 12,048 ODP kilograms.", "The chlorofluorocarbon metered-dose inhalers (CFC-MDIs) listed in Annex I shall not be placed on markets that have determined CFCs for these products to be non-essential.", "During the period 1 January to 31 December 2005 the following rules shall apply:\n1. The allocation of essential medical use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 shall be to the companies indicated in Annex II.\n2. The allocation of essential laboratory use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115 and other fully halogenated chlorofluorocarbons shall be to the companies indicated in Annex III.\n3. The allocation of essential laboratory use quotas for halons shall be to the companies indicated in Annex IV.\n4. The allocation of essential laboratory use quotas for carbon tetrachloride shall be to the companies indicated in Annex V.\n5. The allocation of essential laboratory use quotas for 1,1,1-trichloroethane shall be to the companies indicated in Annex VI.\n6. The allocation of essential laboratory use quotas for hydrobromofluorocarbons shall be to the companies indicated in Annex VII.\n7. The allocation of essential laboratory use quotas for bromochloromethane shall be to the companies indicated in Annex VIII.\n8. The essential use quotas for chlorofluorocarbons 11, 12, 113, 114 and 115, other fully halogenated chlorofluorocarbons, carbon tetrachloride, 1,1,1-trichloroethane, hydrobromofluorocarbons and bromochloromethane shall be as set out in Annex IX.", "This Decision is addressed to the following undertakings:\n3M Health Care Ltd\n3M House Morley Street\nLoughborough\nLeicestershire LE11 1EP\nUnited Kingdom\nAventis\nLondon Road, Holmes Chapel\nCheshire CW4 8BE\nUnited Kingdom\nBespak PLC\nNorth Lynn Industrial Estate\nKing's Lynn\nPE30 2JJ \u2014 Norfolk\nUnited Kingdom\nBoehringer Ingelheim GmbH\nBinger Stra\u00dfe 173\nD-55216 Ingelheim am Rhein\nChiesi Farmaceutici SpA\nVia Palermo 26/A\nI-43100 Parma\nGlaxoSmithKline\nSpeke Boulevard\nSpeke\nL24 9JD \u2014 Liverpool\nUnited Kingdom\nIG Spr\u00fchtechnik GmbH\nIm Hemmet 1\nD-79664 Wehr\nInyx Pharmaceuticals Ltd\nAstmoor Industrial Estate\n9 Arkwright Road RUNCORN\nCheshire WA7 1NU\nUnited Kingdom\nGlaxoSmithKline Pharmaceuticals SA\nSiedziba w Poznaniu\nul. Grunwaldzka 189\n60-322 Pozna\u0144\nPoland\nIVAX Ltd\nUnit 301 Industrial Park\nWaterford\nIreland\nLaboratorio Aldo Union SA\nBaronesa de Mald\u00e1, 73\nEspluges de Llobregat\nE-08950 Barcelona\nSICOR S.p.A\nVia Terrazzano 77\nI-20017 Rho (MI)\nValeas SpA Pharmaceuticals\nVia Vallisneri, 10\nI-20133 Milano\nValois SA\n50, avenue de l'Europe\nF-78160 Marly Le Roi\nValvole Aerosol Research Italiana (VARI)\nSpa \u2014 LINDAL Group Italia\nVia del Pino, 10\nOlginate (LC)\nI-23854\nAcros Organics bvba\nJanssen Pharmaceuticalaan 3a\nB-2440 Geel\nAgfa-Gevaert NV\nSeptestraat 27\nB-2640 Mortsel\nBie & Berntsen\nSandb\u00e6kvej 7\nDK-2610 R\u00f8dovre\nBiosolove BV\nWaalreseweg 17\n5554 HA Valkenswaard\nNederland\nCarl Roth GmbH\nSchoemperlenstra\u00dfe 3\u20145\nD-76185 Karlsruhe\nElcom Group\nOkru\u017en\u00ed 988\nCZ-735 14 Orlov\u00e1-Lutyn\u011b\nHealth Protection Inspectorate-Laboratories\nPaldiski mnt 81\nEE-10617 Tallinn\nHoneywell Specialty Chemicals\nWunstorfer Stra\u00dfe 40\nPostfach 100262\nD-30918 Seelze\nIneos Fluor Ltd\nPO Box 13, The Heath\nRuncorn Cheshire WA7 4QF\nUnited Kingdom\nInstitut scientifique de service public (ISSeP)\nRue du Ch\u00e9ra, 200\nB-4000 Li\u00e8ge\nKatholieke Universiteit Leuven\nKrakenstraat 3\nB-3000 Leuven\nLGC Promochem GmbH\nMercatorstra\u00dfe 51\nD-46485 Wesel\nMallinckrodt Baker BV\nTeugseweg 20\n7418 AM Deventer\nNederland\nMerck KGaA\nFrankfurter Stra\u00dfe 250\nD-64293 Darmstadt\nMikro+Polo d.o.o.\nZagreb\u0161ka cesta 22\nSI-2000 Maribor\nMinistry of Defense\nDirectorate Material RNLNavy\nPO Box 2070\n2500 ES The Hague\nNederland\nPanreac Quimica SA\nRiera de Sant Cugat, 1\nE-08110 Montcada I Reixac (Barcelona)\nRohs Chemie GmbH\nBerliner Str. 54\nD-53819 Neunkirchen-Seelscheid\nSanolabor d.d.\nLeskov\u0161kova 4\nSI-1000 Ljubljana\nSDS Solvants, Documentation, Synth\u00e8ses SA\nZ.I. de Valdonne, BP 4\nF-13124 Peypin\nSigma Aldrich Chemie GmbH\nRiedstra\u00dfe 2\nD-89555 Steinheim\nSigma Aldrich Chimie SARL\n80, rue de Luzais\nL'Isle-d'Abeau Chesne\nF-38297 Saint-Quentin-Fallavier\nSigma Aldrich Company Ltd\nThe Old Brickyard\nNew Road Gillingham SP8 4XT\nUnited Kingdom\nSigma Aldrich Laborchemikalien\nWunstorfer Stra\u00dfe 40, Postfach 100262\nD-30918 Seelze\nVWR I.S.A.S.\n201 rue Carnot\nF-94126 Fontenay-sous-Bois\nYA-Kemia Oy \u2014 Sigma-Aldrich Finland\nTeerisuonkuja 4\nFI-00700 Helsinki", "This Decision shall apply from 1 January 2005 and shall expire on 31 December 2005."], "attachments": "Done at Brussels, 23 August 2005.\nFor the Commission\nStavros DIMAS\nMember of the Commission\n(1)\u00a0\u00a0OJ L 244, 29.9.2000, p. 1. Regulation as last amended by Commission Regulation (EC) No 2077/2004 (OJ L 359, 4.12.2004, p. 28).\n(2)\u00a0\u00a0www.unep.org/ozone/dec12-2-3.shtml\n(3)\u00a0\u00a0OJ C 187, 22.7.2004, p. 24.\n(4)\u00a0\u00a0Ozone-depleting Potential.\nANNEX I\nPursuant to paragraph 3 of Decision XII/2 of the Twelfth Meeting of the Parties to the Montreal Protocol on measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers (MDIs), the following countries have determined that, due to the presence of suitable non-CFC MDIs, CFCs no longer qualify as \u2018essential\u2019 under the Protocol when combined with following active ingredients:\nCountry Salbutamol Terbutaline Fenoterol Orciprenaline Reproterol Carbuterol Hexoprenaline Pirbuterol Clenbuterol Bitolterol Procaterol Beclamethasone Dexamethasone Flunisolide Fluticasone Budesonide Triamcinolone Ipratropium bromide Oxitropium bromide\nAustria\nBelgium\nCyprus\nCzech Republic\nDenmark\nEstonia\nFinland\nFrance\nGermany\nGreece\nHungary\nIreland\nLatvia\nLithuania\nLuxembourg\nPoland\nPortugal\nThe Netherlands\nNorway\nSlovak Republic\nSlovenia\nSpain\nSweden\nUK\nSource: www.unep.org/ozone/Information_for_the_Parties/3Bi_dec12-2-3.asp\nANNEX II\nESSENTIAL MEDICAL USES\nQuota of controlled substances of Group I that may be used in the production of metered dose inhalers (MDIs) for the treatment of asthma and other chronic obstructive pulmonary diseases (COPDs) are allocated to:\n3M Health Care (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nAventis (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBespak (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBoehringer Ingelheim (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nChiesi (IT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nGlaxo Smith Kline (ES, FR, PL, UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nIG Spr\u00fchtechnik (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nInyx Pharmaceuticals (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nIVAX (IE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nLaboratorio Aldo-Uni\u00f3n (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSicor (IT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nV.A.R.I. (IT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nValeas (IT)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nValois (FR)\n3M Health Care (UK)\nAventis (UK)\nBespak (UK)\nBoehringer Ingelheim (DE)\nChiesi (IT)\nGlaxo Smith Kline (ES, FR, PL, UK)\nIG Spr\u00fchtechnik (DE)\nInyx Pharmaceuticals (UK)\nIVAX (IE)\nLaboratorio Aldo-Uni\u00f3n (ES)\nSicor (IT)\nV.A.R.I. (IT)\nValeas (IT)\nValois (FR)\nANNEX III\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group I and II that may be used for laboratory and analytical uses, are allocated to:\nAgfa-Gevaert (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBie & Berntsen (DK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBiosolve (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nCarl Roth (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nElcom Group (CZ)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nHoneywell Specialty Chemicals (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nIneos Fluor (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nKatholieke Universiteit Leuven (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nLGC Promochem (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMallinckrodt Baker (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMerck KGaA (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMikro + Polo (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nPanreac Qu\u00edmica (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSDS Solvants (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSanolabor (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\nAgfa-Gevaert (BE)\nBie & Berntsen (DK)\nBiosolve (NL)\nCarl Roth (DE)\nElcom Group (CZ)\nHoneywell Specialty Chemicals (DE)\nIneos Fluor (UK)\nKatholieke Universiteit Leuven (BE)\nLGC Promochem (DE)\nMallinckrodt Baker (NL)\nMerck KGaA (DE)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nSDS Solvants (FR)\nSanolabor (SI)\nSigma Aldrich Chemie (DE)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nANNEX IV\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group III that may be used for laboratory and analytical uses are allocated to:\nIneos Fluor (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMinistry of Defense (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\nIneos Fluor (UK)\nMinistry of Defense (NL)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nANNEX V\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group IV that may be used for laboratory and analytical uses, are allocated to:\nAcros Organics (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nAgfa-Gevaert (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBie & Berntsen (DK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBiosolve (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nHealth Protection Inspectorate-Laboratories (EE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nInstitut Scientifique de Service Public (ISSeP) (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nKatholieke Universiteit Leuven (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMallinckrodt Baker (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMerck KGaA (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMikro + Polo (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nPanreac Qu\u00edmica (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nRohs Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSDS Solvants (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSanolabor d.d. (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Laborchemikalien (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nVWR I.S.A.S. (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nYA-Kemia Oy (FI)\nAcros Organics (BE)\nAgfa-Gevaert (BE)\nBie & Berntsen (DK)\nBiosolve (NL)\nHealth Protection Inspectorate-Laboratories (EE)\nInstitut Scientifique de Service Public (ISSeP) (BE)\nKatholieke Universiteit Leuven (BE)\nMallinckrodt Baker (NL)\nMerck KGaA (DE)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nRohs Chemie (DE)\nSDS Solvants (FR)\nSanolabor d.d. (SI)\nSigma Aldrich Chemie (DE)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nSigma Aldrich Laborchemikalien (DE)\nVWR I.S.A.S. (FR)\nYA-Kemia Oy (FI)\nANNEX VI\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group V that may be used for laboratory and analytical uses are allocated to:\nAcros Organics (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nBie & Berntsen (DK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nKatholieke Universiteit Leuven (BE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMallinckrodt Baker (NL)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMerck KGaA (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nMikro + Polo (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nPanreac Qu\u00edmica (ES)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSanolabor d.d. (SI)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chemie (DE)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nVWR I.S.A.S. (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nYA-Kemia Oy (FI)\nAcros Organics (BE)\nBie & Berntsen (DK)\nKatholieke Universiteit Leuven (BE)\nMallinckrodt Baker (NL)\nMerck KGaA (DE)\nMikro + Polo (SI)\nPanreac Qu\u00edmica (ES)\nSanolabor d.d. (SI)\nSigma Aldrich Chemie (DE)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nVWR I.S.A.S. (FR)\nYA-Kemia Oy (FI)\nANNEX VII\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group VII that may be used for laboratory and analytical uses are allocated to:\nIneos Fluor (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chimie (FR)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Company (UK)\nIneos Fluor (UK)\nSigma Aldrich Chimie (FR)\nSigma Aldrich Company (UK)\nANNEX VIII\nESSENTIAL LABORATORY USES\nQuota of controlled substances of Group IX that may be used for laboratory and analytical uses are allocated to:\nIneos Fluor (UK)\n\n\n\n\n\n\n\n\n\n\n\u00a0\n\n\nSigma Aldrich Chemie (DE)\nIneos Fluor (UK)\nSigma Aldrich Chemie (DE)\nANNEX IX\n(This Annex is not published because it contains confidential commercial information.)"}